Johnson & Johnson Finalizes National Opioid Settlement Agreement
J&J to contribute up to $5 billion to the settlement agreement to resolve opioid-related claims and litigation in the United States.
Johnson & Johnson and its US-based Janssen Pharmaceutical Companies announced in a July 21, 2021 press release a nationwide settlement agreement has been finalized to resolve opioid-related claims and litigation in the United States.
This settlement agreement aims to resolve most of the litigation-based claims regarding the past sales of the company’s prescription opioid medications. According to the press release, the agreement isn’t an admission of any liability or wrongdoing, and the company said it will defend against any litigation that the final agreement doesn’t resolve.
The company announced in a previous statement it will contribute up to $5 billion to the settlement. This will depend on how many state and local governments opt into the agreement in the next several months.
According to the July 21, 2021 press release, the company said its the marketing and promotion of prescription opioid medications were appropriate and responsible. Since the US launch, DURAGESIC, NUCYNTA, and NUCYNTA ER accounted for less than 1% of total opioid prescriptions.
Johnson & Johnson no longer sells prescription opioid medications in the US.
Source: Johnson & Johnson
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
